Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Manufacturing source : Www.kempharm.com save search
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
Published: 2021-11-10 (Crawled : 22:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 2.64%
H: 3.75%
C: 0.21%
SEEL | $0.3502 3.61% 3.48% 290K
|
Health Technology
|
| O: 0.0%
H: 1.83%
C: -0.92%
HSTO 1 d | $0.5 67.46% 530
|
Health Technology
|
| O: 3.17%
H: 0.7%
C: -6.09%
financial results results
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
Published: 2021-10-27 (Crawled : 12:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: -0.39%
H: 2.25%
C: -1.17%
presentation treatment adhd
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
Published: 2021-10-19 (Crawled : 12:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 1.81%
H: 2.93%
C: 1.25%
nasdaq
KemPharm Reports Second Quarter 2021 Financial Results
Published: 2021-08-12 (Crawled : 21:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: -9.22%
H: 4.43%
C: -1.62%
financial results results
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
Published: 2021-07-21 (Crawled : 13:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 1.8%
H: 3.0%
C: 0.35%
treatment adhd
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
Published: 2021-06-18 (Crawled : 13:15) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: -2.07%
H: 0.39%
C: -8.05%
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status
Published: 2021-05-26 (Crawled : 12:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 0.4%
H: 0.2%
C: -1.89%
patent
KemPharm Reports First Quarter 2021 Financial Results
Published: 2021-05-13 (Crawled : 21:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 1.41%
H: 6.48%
C: 5.44%
financial results results report
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
Published: 2021-05-07 (Crawled : 12:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 2.71%
H: 6.94%
C: 4.63%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.